BCHE and Cognitive impairment: Consequently, cholinesterase inhibitors have become a fundamental approach in AD treatment.526 Targeting both AChE and Butyrylcholinesterase (BuChE) not only alleviates cognitive impairment in AD patients by increasing ACh levels but also serves as a disease-modifying agent, delaying the formation of Aβ plaques.527–529 The dual inhibitor of AChE and BuChE, compound 45, significantly enhanced the learning and memory abilities of aged AD mice.